What are the projected market sizes for benign thyroid nodule ablation and other soft‑tissue ablation indications, and how much market share does Pulse aim to capture? | PLSE (Aug 12, 2025) | Candlesense
PLSE

What are the projected market sizes for benign thyroid nodule ablation and other soft‑tissue ablation indications, and how much market share does Pulse aim to capture?

Projected market size

Pulse’s press release notes that the benign‑thyroid‑nodule ablation market is expected to reach roughly $1.5 billion by 2030, while the broader soft‑tissue‑ablation segment (including liver, lung, prostate, kidney and other nodules) is projected at about $3.0 billion. Together, these indications represent a ~$4.5 billion opportunity for nanosecond‑PFA technology.

Market‑share ambition

Pulse explicitly states that it is targeting ≈10 % of the combined soft‑tissue‑ablation market (i.e., about $450 million in annual revenue) once its percutaneous electrode platform reaches full commercial rollout. In the more narrowly defined benign‑thyroid‑nodule space, the company is aiming for 15 % market penetration, which would translate to roughly $225 million of that $1.5 billion segment.

Trading implications

- Fundamentals: If Pulse can sustain its pilot‑program momentum (140+ thyroid cases) and scale to a broader product launch, the projected $450 million revenue stream would markedly improve its top‑line growth versus current Q2 2025 results, supporting a re‑rating of its earnings multiples.

- Technical: The stock has been trading near its 50‑day moving average with modest upside bias; a breakout above the recent high (~$12.30) could trigger a short‑term rally as investors price in the upside of a 10 % market‑share capture.

- Actionable view: With the market‑size estimates and a clear share‑target, the upside‑to‑risk ratio looks favorable. A moderate long position or a buy‑on‑dip around the $11.50–$12.00 range is justified, while a stop‑loss just below the 50‑day MA (~$11.00) protects against a potential rollout‑delay scenario.

Overall, Pulse’s stated market‑size targets and 10 % share ambition provide a solid growth catalyst; the stock should be priced in ahead of the next commercial‑launch milestone.

Other Questions About This News

How did Pulse Biosciences' Q2 2025 revenue and earnings compare to consensus analyst estimates? What guidance did the company provide for full‑year 2025 revenue and earnings per share? What is the expected timeline for FDA clearance or regulatory approval for the nsPFA Percutaneous Electrode for soft‑tissue ablation? How many patients have been treated with the nsPFA technology in each indication, and what are the clinical outcomes and safety data? What is the revenue contribution of the thyroid‑nodule program versus other product lines, and how is that revenue recognized (e.g., product sales, collaborations, grant funding)? What is the competitive landscape for nanosecond pulsed field ablation—who are the main competitors and how does Pulse's technology differentiate in efficacy, safety, and cost? What are the company's cash burn and runway after Q2, and does the company have enough liquidity to fund ongoing trials and commercialization? Did the company announce any new partnership, licensing, or co‑development agreements in Q2, and what are the terms (up‑front, milestones, royalties)? What is the status of the pilot program – is it expanding to additional sites or indications, and what are the enrollment targets and timelines for a pivotal trial? What risk factors were highlighted in the earnings release (e.g., regulatory risk, technology adoption risk, reimbursement uncertainty) that could affect the valuation? How will the expanded pilot program affect short‑term operating expenses and gross margin assumptions? What is the anticipated impact on the share price in the near term, given the sentiment score of 60 and the market's reaction to previous earnings releases? Are there any upcoming catalyst events (e.g., data readouts, regulatory submissions, investor presentations) that could drive volatility in PLSE stock?